## Citation
Curto, Martina, Luana Lionetto, Andrea Negro, Matilde Capi, Francesco Fazio, Maria Adele Giamberardino, Maurizio Simmaco, Ferdinando Nicoletti, and Paolo Martelletti. 2016. “Altered kynurenine pathway metabolites in serum of chronic migraine patients.” The Journal of Headache and Pain 17 (1): 47. doi:10.1186/s10194-016-0638-5. http://dx.doi.org/10.1186/s10194-016-0638-5.

## Published Version
doi:10.1186/s10194-016-0638-5

## Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320356

## Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Altered kynurenine pathway metabolites in serum of chronic migraine patients

Martina Curto1,2†, Luana Lionetto3†, Andrea Negro2,4, Matilde Capi3, Francesco Fazio5, Maria Adele Giamberardino6, Maurizio Simmaco3, Ferdinando Nicoletti5,7 and Paolo Martelletti2,4

Abstract

Background: Activation of glutamate (Glu) receptors plays a key role in the pathophysiology of migraine. Both NMDA and metabotropic Glu receptors are activated or inhibited by metabolites of the kynurenine pathway, such as kynureninic acid (KYNA), quinolinic acid (QUINA), and xanthurenic acid (XA). In spite of the extensive research carried out on KYNA and other kynurenine metabolites in experimental models of migraine, no studies have ever been carried out in humans. Here, we measured all metabolites of the kynurenine pathway in the serum of patients affected by chronic migraine (CM) and age- and gender-matched healthy controls.

Methods: We assessed serum levels of tryptophan (Trp), L-ky

Background

Among primary headache disorders, migraine is common in clinical practice [1]. It is characterized by a natural fluctuation between a low and a high frequency pattern under the influence of modifiable and non-modifiable risk factors [2]. Increased attack frequency may lead to the so-called 'chronic migraine' (CM), which becomes less responsive to both acute and prophylactic treatments. CM is associated with significant disability and high socioeconomic impact [3, 4], which make CM a major public health problem [5, 6]. In spite of the increasing number of drugs marketed for the treatment of migraine, a substantial proportion of patients do not respond to medication, and are therefore at risk for chronicization [7].

Four not-mutually-exclusive mechanisms have been implicated in the pathophysiology of migraine: (i) peripheral
sensitization of the trigeminovascular system; (ii) central sensitization of the caudal trigeminal nucleus and other central nervous system (CNS) structures of the pain neuraxis; (iii) activation of brainstem migraine generators; and, (iv) cortical spreading depression, underlying aura phenomenon of migraine with aura [8]. All these processes are mediated by allostatic changes in mechanisms of activity-dependent synaptic plasticity, such as long-term potentiation (LTP) and long-term depression (LTD). Glutamate (Glu), the major excitatory neurotransmitter, is involved in the induction and expression of both LTP and LTD, and, therefore, extensive research has focused on the role of glutamatergic transmission in the pathophysiology of migraine. N-methyl-D-aspartate (NMDA) receptors, have an established role in mechanisms of central sensitization [9, 10] and in the onset and propagation of cortical spreading depression [11, 12]; in addition, an association has been found between migraine and polymorphisms in genes involved in the regulation of synaptic Glu uptake and postsynaptic Glu signaling [13–15]. Increased plasma and cerebrospinal fluid Glu levels have been reported in patients affected by migraine [16, 17], but the interpretation of these findings is limited by the large prevalence of the metabolic pool of Glu with respect to the neurotransmitter pool. Investigation on other endogenous ligands of Glu receptors in patients affected by migraine is limited. The KP of Trp metabolism generates a series of compounds that interact with Glu receptors, and, therefore, have been implicated in the pathophysiology of migraine [18]. The pathway is activated by either indolamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO), which transform L-tryptophan into N-formyllkynurenine. L-kynurenine (KYN), 3-hydroxykynurenine (3-HK), kynurenic acid (KYNA) anthranilic acid (ANA), xanthurenic acid (XA), 3-hydroxyanthranilic acid (3-HANA) and quinolinic acid (QUINA) are metabolites of L-kynurenine (KYN). KYN, its precursor, KYN, on the trigeminovascular system or cortical spreading depression has been the subject of extensive investigation, and pharmacological strategies aimed at enhancing KYNA synthesis have been suggested in migraine [8] (see also Discussion and References therein).

To our knowledge, no measurements of kynurenine metabolites have been performed in the plasma of patients affected by migraine or other forms of chronic headache. This aspect is not trivial because brain levels of IDO and TDO are low, and peripheral L-kynurenine and 3-HK fuel the kynurenine pathway in the CNS [19]. Here we report the surprising finding that ANA levels are substantially increased in the plasma of patients affected by CM, at the expenses of all other kynurenine metabolites with the notable exception of XA.

**Methods**

**Patients**

The protocol was carried out in accordance with the declaration of Helsinki and the study design was reviewed and approved by the Ethical Committee at Sapienza, University of Rome, Sant’Andrea Hospital. All subjects signed free informed consent for participation in the study. All subjects were enrolled by the Regional Referral Headache Center of S. Andrea Hospital and evaluated by two experts in headache disorders (A.N. and P.M.). 119 patients met the ICHD-3 beta criteria for CM and were included in the CM group, and 84 healthy subjects were included in the age-matched control group. Inclusion criteria for CM patients were: (i) age between 18 and 75 years; (ii) patients treated with OnabotulinumtoxinA for the prophylactic therapy (iii) patients treated with triptans or any other analgesics during the headache attacks.

Exclusion criteria were: (i) the presence of psychiatric co-morbidities, immunological disorders, endocrine disorders, neurological disorders, and mental retardation; (ii) lifetime history of migraine (for healthy volunteers); and (iii) the use of any drug of abuse in the last 3 months (except cigarette smoking). Both patients in an attack free and in a pain period were included.

**Blood collection and KP measurement**

Serum samples from patients and controls were collected between 10 am and 12 am. Blood (5 ml) was sampled in anticoagulant-free tubes and kept at room temperature for 1 h before the serum was isolated (centrifugation at 2000 g for 10 min at 20 °C).

We developed a liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the assay of serum levels of all kynurenine metabolites. The method allowed a reliable detection of KYN, KYNA, ANA, 3-HANA, 3-HK, XA, and QUINA. Levels of Trp and 5-HIAA were also detected. Details on sample preparation, reagents, standard solutions, chromatographic conditions, mass spectrometry conditions, and validation parameters are reported in Fazio et al. [20].

**Statistical analysis**

SPSS version 19.00 (IBM Corporation, Armonk NY, USA) was used for data analysis. Continuous variables...
were expressed as mean standard ± deviation (SD), while discrete variables were assigned as numbers and percentages. The compliance of continuous variables with normal distribution was controlled with the Kolmogorov–Smirnov test. Whether Healthy Controls and Cluster Headache groups differed in terms of discrete variables was checked through Pearson’s Chi Squared test (\(\chi^2\)). Since continuous variables did not comply with a normal distribution, the Mann–Whitney U test was used for between group comparisons. We set statistical significance at \(P \leq 0.05\).

**Results**

Demographic characteristics of patients affected by CM \((n = 119)\) and age-matched healthy controls (HCs) \((n = 84)\) are shown in Table 1. The CM group, as expected, showed a prevalence of female gender (72.3 %), which did not differ from the percentage of female gender in the selected HCs (82.1 %). Mean age was 44 and 40 years in patients affected by CM and in HCs, respectively (see Table 1).

LC-MS/MS analysis of kynurenine metabolites showed significant reductions in serum levels of KYN (−32 %), KYNA (−25 %), 3-HK (−49 %), 3-HANA (−63 %), and
QUINA (~80%). Surprisingly, ANA levels were largely increased (+339 %) in the serum of patients affected by CM. XA levels were also increased in CM patients, but to a lower extent (+28 %). We extended the analysis to the precursor L-Trp, and the serotonin metabolite, 5-HIAA. We found a small, but significant, increase in Trp levels (+5%) associated with a substantial reduction in 5-HIAA levels in the serum of patients affected by CM (Table 1, Fig. 2). No difference between serum levels of any kynurenine metabolites was found between male and female subjects in CM patients and HCs (not shown).

**Discussion**

We have shown for the first time that CM is associated with abnormalities of the kynurenine pathway, as reflected by changes in serum levels of KYN and all downstream metabolites. An important question in all studies in which putative neuroactive molecules are measured in peripheral blood is whether, and to what extent, blood levels reflect putative neuroactive molecules that lie downstream of KYN. This is unusual, and we are not aware of any other conditions in which a large accumulation of ANA is associated with a reduction of most of all other kynurenine metabolites. The large accumulation of ANA suggests that its transformation into 3-HANA is largely reduced in migraine. The significant increase in XA levels found in CM patients is also difficult to explain because the enzyme Kynurenine Aminotransferase (KAT), which transaminates 3-HK into XA also converts KYN into XA. However, this hypothesis could not be tested because of the incomplete knowledge of XA catabolism.

We will attempt to correlate these changes to the pathophysiology of migraine to the best of our knowledge. The study of kynurenine metabolites in models of migraine has been focused on KYNA, which displays pleiotropic actions in the CNS by inhibiting NMDA receptors and a7-nicotinic acetylcholine receptors, and activating the GPR35 G-protein coupled receptor [22]. KYN (boosted with probenecid) or synthetic analogues of KYNA given systemically inhibit the activation of the caudal trigeminal nucleus in experimental animal models of migraine [24–28]. KYN and KYNA also inhibit the development of cortical spreading depression and the associated changes in the permeability of the blood brain barrier, and at least the effect of KYN is modulated by sex hormones [22, 29, 30]. Taken together, these findings suggest that KYNA has a protective role against migraine by restraining the activation of NMDA receptors. The reduction in KYNA levels we have seen in the serum of CM patients is consistent with the hypothesis that NMDA receptors are overactive in migraine (see Background and References therein).
Interestingly, CSF and serum KYNA levels are increased in patients affected by schizophrenia [19, 20], a CNS disorder characterized by a hypofunction of NMDA receptors [31]. Thus, peripheral KYNA levels might represent a reliable indicator of NMDA receptor function in distinct CNS disorders.

One might argue that the large reduction in serum QUINA levels we have seen in CM patients may limit the activation of NMDA receptors in migraine because QUINA behaves as an orthosteric NMDA receptor agonist [32]. However, migraine is characterized by an increased glutamatergic transmission [8, 11], and, under these conditions, NMDA receptors may be fully activated by the high synaptic Glu levels combined with low KYNA levels. Thus, at least in migraine, the reduction in KYNA levels might facilitate NMDA receptor activation in spite of the simultaneous reduction in QUINA levels.

Recent findings suggest that XA activates mGlu2 and mGlu3 receptors [20], although XA may also indirectly influence glutamatergic transmission by interacting with vesicular Glu transporters [33, 34]. mGlu2 receptors negatively modulate pain transmission, and drugs that activate or induce mGlu2 receptors are promising candidates in the experimental treatment of migraine (reviewed by Chiechio et al., [35]). Hence, the increase in XA levels we have found in CM patients may represent a compensatory event aimed at reinforcing endogenous analgesic mechanisms in migraine. In this particular case, the high Glu levels may not compete with XA because mGlu2 receptors are preferentially localized in the pre-terminal region of nerve terminals, and are therefore not accessible to synaptically released Glu (reviewed by Nicoletti et al., [36]).

Finally, the functional significance of the large increase in ANA levels we have seen in CM patients is obscure. No specific function or receptor targets for ANA have been described to date. Our findings strongly encourage the study of ANA in models of pain in general and of migraine in particular.

**Fig. 2** Percent changes in serum kynurenine metabolites in patients affected by CM with respect to healthy controls. Data are presented as per cent of HC values for each metabolite. Values are means ± S.E.M. *p < 0.05 vs. healthy controls (HCs).
Conclusions
In conclusion, we have demonstrated for the first time that CM is associated with abnormalities of the kynurenine pathway metabolites. In particular, we found a reduction of KYNA levels with a simultaneous reduction in QUINA levels and increase in XA and ANA levels. KYNA reduction and QUINA increase are consistent with the hypothesis that NMDA receptors are overactive in migraine, and the increase in XA levels may represent a compensatory event aimed at reinforcing endogenous analgesic mechanisms in migraine. Since ANA specific functions or targets are unknown, the significance of its large increase in CM is obscure and these findings strongly encourage the study of ANA in models of migraine.

Competing interests
AH received travel grants, honoraria consultancy and participated in Advisory Board from Allergan, ElectroCore, and Medtronic. PM received travel grants, honoraria consultancy and participated in Advisory Board from Allergan, Medtronic, and Mylan.
MC, MC, FF, FN, MS, LL, MAG: none.
This research project received no specific grant from any funding agency in the public, commercial, or not-profit sectors.

Authors’ contributions
MC, LL and PM designed the protocol. AN and PM recruited patients and collected the blood. MC, FF and LL performed the assessment of kynurenine serum levels. MC and FN reviewed statistic content. MC and LL drafted the manuscript. PM, MAG, MS and FN reviewed critically the final draft. All authors read and approved the final manuscript.

Disclosures
No author or any immediate family member has financial relationships with commercial organizations that might appear to present a potential conflict of interest with the material presented.

Author details
1Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
2Department of Molecular Medicine, Sant’Andrea Medical Center, Sapienza University, Via di Grottarossa 1035-1039, Rome 00189, Italy.
3Advanced Molecular Diagnostics, IDRCSS, Rome, Italy.
4Regional referral headache center, Sant’Andrea Hospital, Rome, Italy.
5IDRCSS Neuromed, Pozzilli, Italy.
6Headache Center and Geriatrics Clinic, Department of Medicine and Science of Aging, “G. D’Annunzio” University, Chieti, Italy.
7Department of Physiology and Pharmacology, Sapienza University, Rome, Italy.

Received: 16 January 2016 Accepted: 12 April 2016
Published online: 29 April 2016

References
1. Martellelli P, Katsarava Z, Lambi C, Magis D, Bendtsen L, Negro A, Russell MB, Mitakostas DD, Jensen RH (2014) Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain 28:15–4
2. Negro A, D’Alonzo L, Martellelli P (2010) Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med 5:513–9
3. Stein TJ, Birbeck GL, Jensen R, Katsarava Z, Martellelli P, Stovner LJ (2011) The Global Campaign, World Health Organization and Lifting The burden: collaboration in action. J Headache Pain 12:73–4
4. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goosby PJ, Yaron SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martellelli P (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13:61–78
5. Vos M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–96
6. Steiner TJ, Stovner LJ, Birbeck GL (2013) Migraine: the seventh disability. J Headache Pain 14:1
7. Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Akvaisy A, Arcioni R, Martellelli P (2012) Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 17:393–406
8. Vecsei L, Szalárdy L, Fulop F, Toldi J (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Disc 12:684–82
9. Sarchielli P, Di Filippo M, Nardi K, Calabresi P (2007) Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 11:343–51
10. Vilikes M, Mitakostas DD (2007) The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 6:251–7
11. Pietrobon D, Moskowitz MA (2014) Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci 15:379–93
12. Charles AC, Baca SM (2013) Cortical spreading depression and migraine. Nat Rev Neurol 9:37–44
13. Anttila V, Stefansson H, Kalliola M, Toldi J, Terwindt GM et al (2010) International Headache Genetics Consortium. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 42:2686–73
14. Ligthart L, de Vries B, Smith AV, Ickes MA, Amin N, Hottenga JJ, Koelwijn SC et al (2011) Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur J Hum Genet 19:901–7
15. Charman DI, Schürks M, Anttila V, de Vries B, Schminke U, Launer LJ, Terwindt GM et al (2011) Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 43:695–8
16. Peres MF, Zukerman E, Sonne Soares CA, Alonso EO, Santos BF, Faulhaber MH (2004) Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24:735–9
17. Cananz AR, D’Andrea G, Perin F, Zamberlan F, Welch KM (1995) Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 15:132–5
18. Cälte A, Edvinsson L, Vécsei L, Toldi J, Fulop F, Toldi J, Warfvinge K (2015) Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion. J Headache Pain 16:999
19. Schwarz R, Bruno JP, Muchowczy PI, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–77
20. Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ullivieri M, Napoletano F, Cap R, Corigliano V, Scaccianoce S, Canuso A, Miele J, De Fusco A, Di Mennea L, Comparelli A, De Carolis A, Gradini R, Nisticò R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicolleti F, Simmaco M (2015) Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. Sci Rep 5:17799
21. Fazio F, Zappulla C, Notartomaso S, Buscetti C, Bessede A, Scarselli P, Vacca C, Gargaro M, Volpi C, Allegrucci M, Lionetto L, Simmaco M, Belladonna ML, Nicolleti F, Farallón F (2014) Cinnabaric acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology 81:237–43
22. Ohl G, Heredj I, Menshárt A, Cznige Z, Nagy D, Fuzik J, Kocsi K, Knapp L, Krucso G, Ellertt L, Kis Z, Seka T, Fulop F, Párutd A, Taji T, Vécsei L, Toldi J (2013) Unexpected effects of peripheral administered kynurenic acid on cortical spreading depression and related blood–brain barrier permeability. Drug Des Devel Ther 16:981–7
23. Knyihar-Csillik E, Cshaide Z, Okuno E, Krziszt-Péva B, Toldi J, Varga C, Molnár A, Csillik B, Vécsei L (2004) Kynurenic acid and the link between migraine and fibromyalgia. Curr Pain Headache Rep 16:88
24. Knyihar-Csillik E, Cshaide Z, Okuno E, Krziszt-Péva B, Toldi J, Varga C, Molnár A, Csillik B, Vécsei L (2004) Kynurenic acid and the link between migraine and fibromyalgia. Curr Pain Headache Rep 16:88
25. Knyihar-Csillik E, Toldi J, Varga C, Molnár A, Csillik B, Vécsei L (2004) Kynurenic acid and the link between migraine and fibromyalgia. Curr Pain Headache Rep 16:88
immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett 418:122–6
26. Knyihar-Csillik E, Mihaly A, Krisztin-Peva B, Robotka H, Szatmari I, Fulop F, Toldi J, Csillik B, Vecsei L (2008) The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res 61:429–32
27. Vamos E, Párdutz A, Varga H, Bohár Z, Tajti J, Fülop F, Toldi J, Vecsei L (2009) L-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 57:425–9
28. Vamos E, Fejes A, Koch J, Tajti J, Fülop F, Toldi J, Párdutz A, Vecsei L (2010) Kynurenate derivative attenuates the nitroglycerin-induced CamKIIα and CGRP expression changes. Headache 50:834–43
29. Chauvel V, Vamos E, Pardutz A, Vecsei L, Schoenen J, Multon S (2012) Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol 236:207–14
30. Chauvel V, Schoenen J, Multon S (2013) Influence of ovarian hormones on cortical spreading depression and its suppression by L-kynurenine in rat. PLoS ONE 10(8):e82279
31. Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamatergic hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacol 37:4–15
32. Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411–2
33. Bartlett RD, Esslinger CS, Thompson CM, Bridges RJ (1998) Substituted quinolines as inhibitors of L-Glutamate transport into synaptic vesicles. Neuropharmacology 37:839–46
34. Neale SA, Copeland CS, Uebele VN, Thomson FJ, Salt TE (2013) Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacol 38:1060–7
35. Chiechio S, Copani A, Zamataro M, Battaglia G, Gereau RW 4th, Nicoletti F (2010) Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 31:153–60
36. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, Wobelewski JT, Pin JP (2011) Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60:1017–41

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com